Skip to main content
Pfizer enrolls first patient in Duchenne muscular dystrophy study

A Phase Ib trial was launched by Pfizer for its mini-dystrophin drug candidate PF-06939926 to treat patients with Duchenne muscular dystrophy. The company expects to enroll 12 patients in the trial for the drug, which it received as part of its acquisition of Bamboo Therapeutics, and aims to have preliminary results of the study in the first half of 2019.

Full Story: